8-K: Verve Therapeutics Reports Positive Clinical Data and Strong Financial Position

Verve Therapeutics announced positive interim data from its Heart-1 trial, progress in its pipeline, and a strong cash position to fund operations into late 2026.

Summary

• Verve Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting significant progress in its gene editing programs.
• The company presented first human proof-of-concept data for in vivo base editing from the Heart-1 trial of VERVE-101, showing dose-dependent reductions in LDL-C and PCSK9 protein.
• Verve expects to have three in vivo gene editing programs in clinical trials in 2024, targeting PCSK9 and ANGPTL3.
• The company's cash, cash equivalents, and marketable securities totaled $624 million as of December 31, 2023, providing a cash runway into late 2026.
• Verve closed a public offering and private placement in December 2023, raising approximately $157.7 million in net proceeds.
• Collaboration revenue for the year ended December 31, 2023, was $11.8 million, compared to $1.9 million in 2022.
• Research and development expenses were $184.9 million for the year ended December 31, 2023, compared to $130.1 million in 2022.
• The net loss for the year ended December 31, 2023, was $200.1 million, or $3.12 per share, compared to a net loss of $157.4 million, or $2.91 per share, in 2022.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, a solid financial position, and clear plans for future development. The successful capital raise and collaboration with Eli Lilly further boost the positive sentiment.

Positives

• The company demonstrated significant LDL-C and PCSK9 protein reductions with VERVE-101, indicating successful gene editing.
• Verve has a strong cash position, providing financial stability for its clinical programs.
• The company is advancing multiple gene editing programs into clinical trials in 2024.
• The FDA has cleared the IND application for VERVE-101, allowing for US trial sites to be activated.
• Verve has a collaboration with Eli Lilly, providing expertise in cardiometabolic disease.

Negatives

• The company reported a net loss of $200.1 million for the year ended December 31, 2023, which is an increase from the $157.4 million loss in 2022.
• Research and development expenses increased to $184.9 million for the year ended December 31, 2023, from $130.1 million in 2022.
• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval or commercial success.

Risks

• The company's success depends on the outcome of clinical trials, which are subject to risks and uncertainties.
• There is a risk that the company may not be able to replicate positive results from earlier trials in larger clinical trials.
• The company may face challenges in obtaining regulatory approvals for its product candidates.
• Verve may need to raise additional capital in the future to fund its operations.
• The company's technology is novel and may not be successful in treating cardiovascular disease.

Future Outlook

Verve expects to dose the first patient in the United States, complete enrollment in the Heart-1 trial, and provide a data update in 2024. The company also plans to initiate the Heart-2 trial for VERVE-102 and a Phase 1b trial for VERVE-201 in 2024. Verve anticipates its cash runway will extend into late 2026.

Management Comments

• Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics, stated that 2023 was a momentous year for Verve, with significant strides made towards their mission of protecting the world from cardiovascular disease.
• He also highlighted the first proof-of-concept data for in vivo base editing in humans from the Heart-1 clinical trial of VERVE-101.

Industry Context

This announcement is significant in the context of the broader gene editing industry, as it demonstrates the potential of in vivo base editing to treat cardiovascular diseases. The positive clinical data from the Heart-1 trial positions Verve as a leader in this space, and the collaboration with Eli Lilly further validates the company's approach.

Comparison to Industry Standards

• The 55% reduction in LDL-C observed in the Heart-1 trial is comparable to or better than results seen with some existing therapies, such as PCSK9 inhibitors, which typically achieve reductions of around 50-60%.
• The 84% reduction in PCSK9 protein is a strong indicator of the effectiveness of the gene editing approach.
• Companies like Alnylam Pharmaceuticals and Ionis Pharmaceuticals have also made progress in RNA-based therapies for cardiovascular disease, but Verve's gene editing approach offers the potential for a single-course treatment.
• The collaboration with Eli Lilly is similar to other partnerships in the biotech industry, where larger pharmaceutical companies collaborate with smaller biotech firms to access innovative technologies.

Related Party Transactions

• Verve closed a private placement of shares with Eli Lilly and Company.

Stakeholder Impact

• Shareholders will be impacted by the positive clinical data and the company's strong financial position.
• Employees will be impacted by the company's growth and development.
• Patients with HeFH and HoFH may benefit from the potential of Verve's gene editing therapies.
• The collaboration with Eli Lilly may impact suppliers and partners.

Next Steps

• Verve plans to dose the first patient in the United States in the Heart-1 trial.
• The company expects to complete enrollment in the ongoing Phase 1b trial of VERVE-101.
• Verve will provide a data update from the Heart-1 clinical trial in the second half of 2024.
• The company plans to initiate the Heart-2 Phase 1b trial for VERVE-102 in the first half of 2024.
• Verve expects to initiate a Phase 1b trial for VERVE-201 in the second half of 2024.
• Verve plans to initiate a randomized, placebo-controlled Phase 2 clinical trial of either VERVE-101 or VERVE-102 in 2025.

Key Dates

Keywords

gene editing, cardiovascular disease, PCSK9, ANGPTL3, LDL-C, HeFH, HoFH, clinical trials, base editing, VERVE-101, VERVE-102, VERVE-201